A Phase 2 interventional study of TL-925 and Placebo in Allergic Conjunctivitis, sponsored by Telios Pharma, Inc.. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-25.
Sponsored by Telios Pharma, Inc. · Phase 2, Interventional, and Treatment
Among 94 studies in Conjunctivitis, Allergic with a site in United States — 5 open to participants now, 6 under way, 2 of them phase 3. Conjunctivitis, Allergic · United States.
Among the 94 studies in Conjunctivitis, Allergic with a site in United States, this one is the 59th largest by planned enrollment of the 89 interventional ones, is the only one that started in 2025, is one of 24 in phase 2, and was the 91st registered.
210 studies on the registry are indexed under Conjunctivitis, Allergic; 18 are open to participants now.
This study's planned enrollment of 60 is below the median of 87 across 174 interventional studies indexed under Conjunctivitis, Allergic.
Browse Conjunctivitis, Allergic studies →5 of the 94 studies in Conjunctivitis, Allergic with a site in United States are open now, in 12 countries. Each count lists the studies.
Of the 12 Conjunctivitis, Allergic studies recruiting now, 8 (67%) set no upper age limit and 4 (33%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →94 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 1 started in 2025.
Median enrollment 91 across the 89 interventional studies, 100 across the 5 observational. Of the 84 that completed or were terminated, 50 (60%) have results posted.
80 of 94 have an industry lead sponsor. The 10 most frequent:
Telios Pharma, Inc. is the lead sponsor of 11 studies on the registry; 5 are open to participants now.
Telios Pharma, Inc. has 4 studies filed under Conjunctivitis, Allergic — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 94 studies in Conjunctivitis, Allergic with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
In this prospective, Phase 2, randomized, double-masked, vehicle controlled study, approximately 60 eligible subjects will be randomized 1:1 to receive either TL-925 or placebo as topical ophthalmic eye drops administered bilaterally.
The study comprises of a screening and treatment period using the conjunctival allergen challenge model to evaluate TL-925 for the treatment of allergic conjunctivitis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will be dosed in clinic.
Drug: TL-925
Subjects wil be dosed in clinic.
Drug: Placebo
TL-925 is an eye drop.
The composition of the placebo is identical to the active formulation except for the exclusion of the active ingredient.
Ocular Itching
Ocular itching score will be reported by the subject at 3 timepoints after CAC at Visits 4d , 5d, and 6c.
Time frame: 3, 5 and 7 minutes after CAC
Conjunctival Redness
Conjunctival redness score will be evaluated by the investigator at 3 timepoints after CAC at Visits 4d, 5d, and 6c.
Time frame: 7, 15 and 20 minutes after CAC
Started Oct 2025 (actual). Primary completion is estimated for Feb 2026, 4 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: TL-925
Telios Pharma, Inc.